Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome

Bone marrow (BM) involvement in diffuse large B‐cell lymphoma (DLBCL) can be morphologically discordant from the primary tumor. Concordant BM infiltration has been shown associated with a poorer outcome in patients treated with CHOP. In order to evaluate tumor‐related factors leading to BM involvement in DLBCL, we performed an integrated analysis of i) genomic profiles obtained with a high‐density genome wide SNP‐based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly treated with R‐CHOP. BM infiltration was found in 27 of 133 (20%) cases; and it was concordant in 18/27 (67%) cases. Concordant infiltration, but not discordant, influenced negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and higher PD rates. No association with cell of origin was found between BM+ and BM‐ DLBCL. As compared with BM‐ cases, BM+ DLBCL showed absence of 7q gain. Copyright © 2010 John Wiley & Sons, Ltd.

[1]  W. Chan,et al.  Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21 , 2010, British journal of haematology.

[2]  W. Chan,et al.  Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma , 2010, British journal of haematology.

[3]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[4]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[5]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[6]  P. Gaulard,et al.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Y. Bang,et al.  Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement , 2009, Annals of Hematology.

[8]  Marcus Hutter,et al.  Bayesian DNA copy number analysis , 2009, BMC Bioinformatics.

[9]  H. Tagawa,et al.  The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis , 2009, Haematologica.

[10]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[11]  R. Siebert,et al.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge , 2008, Leukemia.

[12]  L. Pasqualucci,et al.  Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma , 2008 .

[13]  A. Rosenwald,et al.  Genomic alterations and gene expression in primary diffuse large B‐cell lymphomas of immune‐privileged sites: the importance of apoptosis and immunomodulatory pathways , 2008, The Journal of pathology.

[14]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[15]  T. Reiman,et al.  Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. , 2007, Blood.

[16]  C. Bloomfield,et al.  Clinical Trials and Observations , 2005 .

[17]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Matthews,et al.  The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement , 2006, European journal of haematology.

[19]  L. Staudt,et al.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.

[20]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[21]  J. Thiele,et al.  Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma--a practical guideline. , 1999, Journal of clinical pathology.

[22]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[23]  H. Höfler,et al.  Discordant Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma: Comparative Molecular Analysis Reveals a Heterogeneous Group of Disorders , 2003, Laboratory Investigation.